Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant

Ioannis Sitaras\textsuperscript{1,5,6}, Henning Jacobsen\textsuperscript{2,5}, Melissa M. Higdon\textsuperscript{3}, William E. Dowling\textsuperscript{1}, Naor Bar-Zeev\textsuperscript{3} and Maria Deloria Knoll\textsuperscript{3}

Virus neutralization data using post-vaccination sera are an important tool in informing vaccine use policy decisions, however, they often pose interpretive challenges. We systematically reviewed the pre-print and published literature for neutralization studies against Omicron using sera collected after both primary and booster vaccination. We found a high proportion of post-primary vaccination sera were not responding against Omicron but boosting increased both neutralizing activity and percent of responding sera. We recommend reporting percent of responders alongside neutralization data to portray vaccine neutralization ability more accurately.

npj Vaccines (2022) 7:147; https://doi.org/10.1038/s41541-022-00565-y

INTRODUCTION
Since its initial characterization in November 2021, the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VOC) has largely displaced the Delta variant in many parts of the world\textsuperscript{1-3}. The World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) among others use information on the neutralizing activity of post-vaccination sera as an early sign of vaccine performance against circulating VOCs. Since neutralization data could inform policy-making decisions regarding vaccine strategies, we reviewed the global evidence for current vaccines' ability to neutralize Omicron, and stratified the results according to primary vaccination series and booster (both of which included homologous and heterologous regimes).

RESULTS
Included studies and number of sera
Neutralization results were extracted from 50 studies meeting our inclusion criteria, providing data for 119 vaccine-specific observations based on 3150 sera (72 observations on 1823 sera for primary vaccination series, and 47 observations on 1327 sera for booster vaccination, Table 1). Details of the included studies and raw data can be found in the Source Data file.

Most primary series and booster observations were of mRNA vaccines (Comirnaty primary: 33/72, booster: 19/47; mRNA-1273 primary: 14/72, booster: 7/47; Table 1). Vaccines with the largest number of sera evaluated were Comirnaty (primary: 777; booster: 438) and BBIBP-CorV (primary: 325; booster: 408). However, most BBIBP-CorV sera originated from one large study of 292 sera. Most (87/119) observations evaluated sera collected 0.5–1 month post-vaccination.

Results stratified by vaccine and regimen
Median fold decreases in Omicron neutralization post-primary vaccination series ranged widely across the vaccines studied, from 6.2-fold (Ad26.COV2.S, IQR 3.0–10.7, 7 observations, 128 sera) to 23.1-fold and 25.5-fold (Comirnaty: IQR 18.9–34.7, 33 observations, 777 sera; mRNA-1273: IQR 15.8–42.6, 14 observations, 275 sera Table 1, Fig. 1A). The percent of responders also ranged widely in primary vaccination series from 0% for CoronaVac to 94% for mRNA-1273 (Table 1 and Fig. 1C). Although the only two heterologous vaccine regimes (Vaxzevria + Comirnaty and Vaxzevria + mRNA-1273) showed 80 and 82% responders respectively, these results were based on only one observation from the same study\textsuperscript{5}.

After a booster dose, median fold decreases in neutralization activity were lower compared to primary vaccination series, ranging from 2.8 (Ad26.COV2.S, 1 observation, 20 sera) and 13.4 (BBIBP-CorV + Anhui ZL heterologous boost, IQR 11.8–14.9, 2 observations, 20 sera, Table 1, Fig. 1B) to 100% response. From the two remaining regimes, Anhui ZL had a 56% response, but the percent response could not be extracted for the one study describing the Vaxzevria + MVC COV1901 regimen (Table 1 and Fig. 1D). The percent of responders correlated with the GMT against the parent strain, which was significantly higher in booster regimes compared to primary series (Table 1).

The median fold decreases against Omicron were generally comparable within the same vaccine class for mRNA (23.1 and 25.5 post-primary; 5.5 and 7.4 post-booster) and for inactivated vaccine classes (7.2 and 9.5 post-primary; 11.4 and 13.1 post-booster) but varied within vector vaccine class (range: 6.2 to 17.5 post-primary, 2.8 and 7.1 post-booster, Table 1).

DISCUSSION
In this review of COVID-19 vaccines' abilities to neutralize the Omicron variant, we show that booster doses increased neutralizing activity compared to primary series vaccination, as evidenced by lesser fold decreases and greater percent of responding sera. The increased activity following the booster dose cannot be explained by prior immune waning, since the vast majority (73%) of included studies evaluated sera collected at peak immunity. We...
also demonstrate that relying only on fold decrease when the percent of responding sera is low can mask the true neutralizing activity of a vaccine, and, consequently, may lead to inaccurate inference of a vaccine’s ability to protect against infection and disease from variants, especially one as antigenically different as Omicron.

The percent of responding sera is an overlooked but highly important parameter in assessing post-vaccination neutralizing activity against variants. The accuracy of fold decrease calculations can be misleading when the majority of sera show no measurable neutralizing activity against Omicron. This is because when serum measurements are below the limit of detection, the general practice is to assign them an arbitrary titer, which is usually either one log lower than the lowest dilution, or half the level of detection. This arbitrary value can have a large impact on the magnitude of the apparent fold change, since it can over- or underestimate neutralizing activity against a variant. It is thus important to also report the percent of responding sera to provide a more complete and accurate picture of a vaccine’s ability to elicit neutralizing immunity against variants.

Table 1. Overview of studies and results.

| Type of vaccination | Platform | Vaccine                  | No. Obs | No. of Sera | Fold decrease (Omicron) | Median % responders (Omicron) | Median GMT (Parent) |
|---------------------|----------|--------------------------|---------|-------------|-------------------------|------------------------------|---------------------|
| Homologous          | Inactivated | BBIBP-CorV              | 4       | 325         | 1.9                     | 7.2                          | 11.2                | 23                  | 67.4                |
|                     |           | CoronaVac                | 4       | 135         | 5.4                     | 9.5                          | 14.5                | 0                   | 32.5                |
| mRNA                |           | mRNA-1273               | 14      | 275         | 15.8                    | 25.5                         | 42.6                | 94                  | 1039                |
|                     |           | Comirnaty               | 33      | 777         | 18.9                    | 23.1                         | 34.7                | 38                  | 347.9               |
| Vector              |           | Vazzevria               | 6       | 131         | 13.3                    | 17.5                         | 25                  | 12                  | 133                 |
|                     |           | Sputnik V               | 2       | 26          | 7.6                     | 7.6                          | 7.6                 | 44.5                | 66.5                |
|                     |           | Ad26.COV2.S            | 7       | 128         | 3.0                     | 6.2                          | 10.7                | 8.5                 | 96                  |
| Heterologous        | Vector + mRNA | Vazzevria + mRNA-1273 | 1       | 11          | 19.5                    | 19.5                         | 19.5                | 82                  | 671.4               |
|                     |           | Vazzevria + Comirnaty   | 1       | 15          | 24.5                    | 24.5                         | 24.5                | 80                  | 661.6               |
| Total               |           |                         | 72      | 1823        |                         |                              |                      |                     |                     |
| Booster             | Homologous | BBIBP-CorV (3 doses)    | 4       | 408         | 8.6                     | 11.4                         | 15.8                | 78                  | 361.8               |
|                     |           | CoronaVac (3 doses)     | 2       | 70          | 9.7                     | 13.1                         | 16.5                | 72.5                | 164.3               |
| mRNA                |           | mRNA-1273 (3 doses)     | 7       | 74          | 4.2                     | 5.5                          | 5.5                 | 100                 | 3942                |
|                     |           | Comirnaty (3 doses)     | 19      | 438         | 4                       | 7.4                          | 13.1                | 100                 | 1749.5              |
| Protein subunit     |           | Anhui ZL (3 doses)      | 3       | 44          | 3                       | 9.4                          | 10.6                | 56                  | 329                 |
|                     | Vector    | Sputnik V + Sputnik Light | 1      | 6          | 7.1                     | 7.1                          | 7.1                 | 100                 | 359.2               |
|                     |           | Ad26.COV2.5 (2 doses)   | 1       | 20          | 2.8                     | 2.8                          | 2.8                 | 100                 | 127.6               |
| Heterologous        | Protein subunit | BBIBP-CorV + Anhui ZL | 2       | 20          | 11.8                    | 13.4                         | 14.9                | 90                  | 1527.5              |
| Inactivated         | + mRNA   | CoronaVac + Comirnaty   | 2       | 85          | 6.1                     | 6.7                          | 7.3                 | 100                 | 320                 |
| mRNA + mRNA         | mRNA     | mRNA-1273 + Comirnaty   | 1       | 4           | 13.1                    | 13.1                         | 13.1                | 75                  | 984.3               |
|                     |          | mRNA-1273 + mRNA-1273   | 1       | 4           | 9.8                     | 9.8                          | 9.8                 | 100                 | 1378.6              |
| mRNA + Vector       | mRNA     | Comirnaty + Ad26.COV2.S | 2       | 61          | 2.9                     | 3.6                          | 4.2                 | 100                 | 2456.3              |
| Vector + mRNA       | Vector   | Ad26.COV2.5 + Comirnaty | 1       | 20          | -                       | -                            | -                   | 100                 | 1044.9              |
|                     | Protein subunit | Vazzevria + MVC-COV1901 | 1       | 73          | 6.6                     | 6.6                          | 6.6                 | N/R                 | 404.8               |
| Total               |           |                         | 47      | 1327        |                         |                              |                      |                     |                     |

Results for each vaccine regimen (primary series and booster), with median fold change against Omicron, IQR, and median GMT against the parent strain (which was chosen to be similar to the vaccine-seed strain). Results could not be extracted; N/R Not Reported. References 4-53 were used to collect the source data used in the analysis, which can be found in the Source Data file.

The lower limit of detection varies greatly between assays that use live viruses versus pseudoviruses. It is important to note, however, that although very low readings can be obtained when using pseudoviruses, the uncertainty connected to these readings increases proportionally the lower the reading is. This holds true for every reading obtained that is already below the lowest (starting) dilution used in the assay. Our suggestion to include the percent of responding sera in the results, helps to eliminate part of this uncertainty.

Induction of high neutralizing titers against the homologous vaccine-seed strain is not only part of regulatory requirements, but also an important early measure of a vaccine’s success, since higher titers generally correspond to higher levels of protection, including against future circulating variants as antigenically different as Omicron. Our analysis shows that GMTs against the parent strain are lower after the primary vaccination series than after the booster dose and corresponded with lower percent of responding sera against Omicron after primary vaccination compared to post-booster dose.
Although some vaccines and vaccine combinations appear to perform better than others, the wide heterogeneity in responses between studies observed for some homologous vaccines mean these data should be considered with caution. This is even more true for all heterologous vaccine combinations evaluated here, where data on their neutralizing ability were available from only 1–2 studies each, and therefore these results may not represent their true abilities. Nevertheless, such data are especially important in the current setting, where reliable clinical effectiveness data may not be available for all vaccines in use, and where administration of heterologous doses can be common because of supply or logistics issues. If meaningful appraisals of vaccine performance are to be made in order to inform timely policy-making decisions, there is an urgent need for more data on the vaccines currently in use. Using the WHO international standard (IS) and reporting results in international units (IU) could in theory allow for better comparison between assays. However, considering that the WHO IS has largely been depleted, and is found to have no neutralizing activity against Omicron variants, reporting the results in IU is not feasible.

A possible limitation of our analysis may come from the inclusion of data from pre-printed articles, which should always be used with caution. Nevertheless, the use of these articles does not affect the main findings and recommendations of this manuscript, namely that neutralizing ability and % of responders against Omicron increase post-boost compared to primary vaccination series, and that there is a need for more data for certain vaccines and vaccine combinations. Both findings hold true regardless of the source of data (published or otherwise). Finally, using pre-prints in order to inform policy-making decisions regarding vaccine strategies has become acceptable during the pandemic, due to urgency of the situation and the need to respond and adjust policies as quickly and effectively as possible. Restricting the analysis to fully published literature would have resulted in the exclusion of relevant and useful data that could help inform our understanding of the impact of Omicron on vaccine performance.

**METHODS**

**Literature search, review, and exclusion criteria**

This work consists of analysis of data available in the public domain. No ethics approval is necessary. Studies containing neutralization data against the Omicron variant after primary series or booster vaccination were identified by searching PubMed and pre-print servers (bioRxiv and medRxiv) from November 1, 2021 until January 31 2022 using the following terms: "SARS-CoV-2" AND "Omicron" AND ("neutralization" or "neutralization"). Title and abstract were screened and those possibly containing relevant data underwent full text review. Studies were screened by three reviewers working independently and collaborating when in doubt. A PRISMA diagram describing the literature search and study selection process is shown in Fig. 2.
Fig. 2 PRISMA flow diagram. Overview of the systematic literature search and study selection process.

Data extraction and analysis
The fold change in neutralizing activity against Omicron (relative to the parent strain), the geometric mean titer (GMT) of the parent strain, and the percent of responding sera (defined as sera with a neutralizing activity against Omicron above each study’s lower limit of detection) were abstracted for each vaccine regimen. All references used to collect the source data can be found in the reference section of this manuscript4–53, as well as in the Source Data file. Raw data can be found in the Source Data file. All neutralization data used were reported as NT50 titers. Median and interquartile ranges (IQR) of the fold decrease in neutralization activity, median percent responders, and median parent strain GMTs across all studies were calculated where possible (using the GMTs reported in each source reference) for each unique vaccine combination and plotted using GraphPad Prism 9 (version 9.3.1). Meta-analyses to estimate average effect size were not performed due to heterogeneity in the methodology of included studies.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
All data generated or analyzed during this study and underlying Fig. 1 are included in this published article and its Source Data file.

Received: 26 March 2022; Accepted: 25 October 2022; Published online: 15 November 2022

REFERENCES
1. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern, https://www.who.int/news/item/26-11-2021-classification-of-omicron-B.1.1.529-sars-cov-2-variant-of-concern (2021).
2. ECDC. SARS-CoV-2 Variants Dashboard, https://www.ecdc.europa.eu/en/covid-19/situation-updates/variants-dashboard (2022).
3. CDC. COVID Data Tracker, https://covid.cdc.gov/covid-data-tracker/variant-proportions (2022).
4. Yu, X. et al. Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discov. 8, 4 (2022).
5. Jacobsen, H. et al. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1 (2021).
6. Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).
7. Basile, K. et al. Improved neutralisation of the SARS-CoV-2 Omicron variant following a booster dose of Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. Viruses 14, 2023 (2022).
8. Ikemura, N. et al. SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.17.21267767v1 (2021).
9. Lu, L. et al. Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or coronaVac vaccine recipients. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1041 (2021).
10. Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N. Engl. J. Med. 386, 492–494 (2021).
11. Gruehl, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477–480 (2022).
12. Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 Omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236 (2022).
13. Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599–601 (2021).
14. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).
15. Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088–1091 (2022).
16. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
17. Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
18. Zeng, C. et al. Neutralization and stability of SARS-CoV-2 Omicron variant. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.16.472934v1 (2021).
19. Zhao, X. et al. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.16.472391v1 (2021).
20. Carreño, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).
21. Syed, A. M. et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc. Natl Acad. Sci. USA 119, e2200592119 (2022).
22. Doližnikova, I. et al. Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.17.21267976v1 (2021).
23. Al, J. et al. Omicron variant showed lower neutralization sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines boosting. Emerg. Microbes Infect. 11, 337–343 (2022).
24. Edara, V. V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. Cell Rep. Med. 3, 100529 (2022).
25. Anien, K. K. et al. Three doses of BNT162b2 vaccine confer neutralizing antibody capacity against the SARS-CoV-2 Omicron variant. npj Vaccines 7, 35 (2022).
26. Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678–680 (2022).
27. Lusvarghi, S. et al. SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.22.2473880v1 (2021).
28. Wang, K. et al. Memory B cell repertoire from triple vaccines against diverse SARS-CoV-2 variants. Nature https://doi.org/10.1038/s41586-022-04466-x (2022).
29. Zhou, R. et al. Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses. Clin. Transl. Med. 12, e720 (2022).
30. Hu, J. et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell. Mol. Immunol. 19, 293–295 (2022).
31. Xiong, W. et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg. Microbes Infect. 11, 477–481 (2022).
32. Tada, T. et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. eBioMedicine https://doi.org/10.1016/j.ebiom.2022.103944 (2022).
33. Pérez-Then, E. et al. Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.22.21268459v1 (2021).
34. Miyamoto, S. et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med 3, 249–261.e244 (2022).
35. van Gils, M. J. et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. *PLoS Med.* 19, e1003991 (2022).

36. Tan, C. S. et al. Homologous and heterologous vaccine boost strategies for humoral and cellular immunologic coverage of the SARS-CoV-2 omicron variant. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.02.21267198v2 (2021).

37. Kotaki, R. et al. Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant. Preprint at https://www.biomedcentral.com/content/10.1186/s12906-022-04749-1v1 (2021).

38. Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. *Nat. Microbiol.* 7, 1161–1179 (2022).

39. Kitchin, D. et al. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. Preprint at https://www.medrxiv.org/content/10.1101/2021.11.08.21266049v3 (2022).

40. Wang, Y. et al. Resistance of SARS-CoV-2 omicron variant to convalescent and CoronaVac vaccine plasma. *Emerg. Microbes Infect.* 11, 424–427 (2022).

41. Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. *Nat. Med.* 28, 486–489 (2022).

42. Baranjee, A. et al. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants. *Med.* 3, 422–432.e423 (2022).

43. Lyke, K. E. et al. SARS-CoV-2 Omicron neutralization after heterologous vaccine boosting. Preprint at https://www.medrxiv.org/content/10.1101/2022.01.13.22268861v1 (2022).

44. Cheng, S.-H., Lin, Y.-C., Chen, C.-P. & Cheng, C.-Y. Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.10.21267574v2 (2022).

45. Liu, J. et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. *Nature* 603, 493–496 (2022).

46. Kaabi, N. A. et al. Immunogenicity and safety of NVSI-06-07 as a homologous booster after priming with BBI-BP-CoV: A phase 2 trial. *Signal Transduct. Target. Ther.* 7, 172 (2022).

47. Xia, H. et al. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. *Cell Host Microbe* 30, 485–486.e483 (2022).

48. Lapa, D. et al. Retention of neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V-vaccinated individuals. *Vaccines* 10, 817 (2022).

49. Seki, Y. et al. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. *Med.* 3, 406–421.e404 (2022).

50. Furukawa, K. et al. Acquired neutralizing breadth against SARS-CoV-2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the vaccine efficacy. Preprint at https://www.medrxiv.org/content/10.1101/2022.01.25.22269735v2 (2022).

51. Girard, B. et al. mRNA-1273 Vaccine-elicted neutralization of SARS-CoV-2 Omicron in adolescents and children. Preprint at https://www.medrxiv.org/content/10.1101/2021.02.01.24.22269666v1 (2022).

52. Gupta, S. L. et al. Loss of Pfzer (BNT162b2) vaccine-induced antibody responses against the SARS-CoV-2 Omicron variant in adolescents and adults. *J. Virol.* 96, e00582–00222 (2022).

53. Chen, L.-L. et al. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. *Emerg. Microbes Infect.* 11, 543–547 (2022).

ACKNOWLEDGEMENTS

We would like to acknowledge Daniel Feikin for his contribution, comments to this manuscript, and his continuous support in efforts to make the evidence useful for policy organizations such as WHO and CEPI. The authors would also like to acknowledge CEPI for funding this work.

AUTHOR CONTRIBUTIONS

I.S.: Literature screening, data collection, study design, analysis, writing – original draft, and review and editing. H.J.: Literature screening, data collection, study design, analysis, and writing – editing. M.H.: Study design, analysis, and writing – editing. W.E.D.: Study design, writing–review and editing, and funding acquisition. N.B.Z.: Writing–review and editing, project management, and supervision. M.D.K.: Study design, writing–review and editing, project management, and supervision. I.S. and H.J. are co-authors and have contributed equally.

COMPETING INTERESTS

M.M.H. reports research grants from Pfizer for unrelated work; M.D.K. reports research grants from Pfizer and Merck and consultancy fees from Merck, all for unrelated work; N.B.Z. reports research grants from Merck, from Johnson & Johnson and from Serum Institute of India, all for unrelated work; and consulting fees from Merck for unrelated work. The rest of the authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information

The online version contains supplementary material available at doi:10.1038/s41541-022-00565-y.

Correspondence

and requests for materials should be addressed to Ioannis Sitaras.

Reprints and permission information

is available at http://www.nature.com/reprints

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.